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Introduction to Written Symposium on Public Health and
International Law
David P. Fidler*
I. INTRODUCTION
Public health has emerged as one of the most important issues of our global age.
Despite health improvements and gains in life expectancy around the world in the
twentieth century, the twenty-first century begins with developed and developing
countries confronting a host of threats to, and controversies about, human health.
The HIV/AIDS pandemic is wreaking enormous damage in the developing world,
especially in sub-Saharan Africa,' and this plague has yet to run its devastating course.
Other infectious diseases, such as malaria, tuberculosis, and diarrheal diseases, are
growing as public health threats around the world.2  A pandemic of non-
communicable diseases related to tobacco consumption is underway, with enormous
morbidity and mortality in developing countries expected in the coming decades.3
Science-one of the engines of public health progress-confronts a controversial
future as scientific developments become tools of malevolent behavior, as with
bioterrorism, and the focus of hopes and fears about the future shape of health and
human nature, as reflected by debates about genetic engineering.
In the face of these challenges, the adequacy of national and international
governance for public health is currently under intense scrutiny. Long a neglected
aspect of the study of international relations and international law, public health has
* Professor of Law and Ira C. Batman Faculty Fellow, Indiana University School of Law,
Bloomington, Indiana.
1. For statistics on the scale of the HIV/AIDS pandemic, see UNAIDS, AIDS Epidemic Update:
December 2001, available online at
<http://www.unaids.org/epidemic._updare/reportdecOl/index.html> (visited Mar 24, 2002).
2. See World Health Organization, Report on Infectious Diseases: Removing Obstacles to Healthy
Development, available online at
<hrtp://www.who.int/infectious-disease-report/pages/textonly.html> (visited Mar 24, 2002).
3. See World Health Organization, Tobacco Free Initiative: Burden of Disease, available online at
<http://tobacco.who.int/page.cfin.sid=47> (visited Mar 24, 2002).
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become prominent and hotly debated within and among states, international
organizations, and global civil society. States have come face-to-face with new disease
threats and the weaknesses of their public health systems to respond effectively. In
the United States, for example, public health now registers in debates about both
national security and homeland defense. Existing international organizations, such as
the United Nations and the World Bank, spend significant time and money on public
health issues. Sensing the challenges globalization poses to public health, the World
Health Organization ("WHO") has attempted to revitalize its ability to fulfill its
mandate. New institutions, such as the World Trade Organization ("WTO"), have
become embroiled in debates about the impact of international trade rules on public
health in developing countries, debates to which non-governmental organizations
("NGOs") have contributed. New global public health regimes are in gestation,
including the Global Fund to Fight AIDS, Tuberculosis, and Malaria' and the
Framework Convention on Tobacco Control Initiatives to underscore the role of
public health in economic development and to create increased flows of public health
funds from rich to poor countries,6 attempt to elevate public health on national and
international agendas.
Reflecting on the growing prominence of public health in world politics and
international law, the Chicago Journal of International Law has chosen to devote
attention to the dynamic relationship that exists between public health and
international law today. This symposium provides a glimpse of the scope and
diversity of areas in which international law and public health intersect, but it does not
exhaust the public health/international law discourse. One theme the symposium
pursues is the controversy regarding the impact that international legal protections
for pharmaceutical patents have had on the access of developing countries to drugs
and medicines. The symposium also reflects the contributors' interest in national and
global public health problems posed by infectious diseases, though this emphasis does
4. See Overview: Global Fund to Fight AIDS, Tuberculosis, and Malaria, available online at
<http://www.globalfundatm.org/overview.html> (visited Mar 24, 2002) (describing itself as "a new
public-private partnership that will make a sustainable and significant contribution to the reduction
of infections, illness and death" caused by AIDS, tuberculosis, and malaria in poor nations).
5. See World Health Organization, Tobacco Free Initiative: Framework Convention on Tobacco Control,
available online at <htrp://tobacco.who.int/page.cfn.pid=40> (visited Mar 24,2002).
6. See, for example, Commission on Macroeconomics and Health, Macroeconomics and Health: Investing
in Health for Economic Development, available online at
<http://www3.who.int/whosis/menu.cfmpath=cmh&language=english> (visited Mar 24, 2002)
(describing the Commission on Macroeconomics and Health, founded in January 2000 to assess the
place of health in global economic development and examine ways of increasing public health
funding to poor countries).
7. For an overview of the role of international law in public health, see generally, David P. Fidler,
International Law and Public Health: Materials on and Analysis of Global Health Jurisprudence
(Transnational 2000).
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not suggest that non-communicable diseases represent insignificant global public
health problems that do not bear on the use or study of international law.' CJIL hopes
that the symposium not only focuses international legal analysis on the contributors'
topics, but also conveys the importance of international law and legal analysis to the
current policy debates concerning how nations, international institutions, and global
civil society work to improve human health globally.
II. BIOTERRORISM
The perpetration of bioterrorism in the United States in 2001 has been
singularly important in raising awareness about the national and global importance of
public health. My contribution analyzes the interaction between bioterrorism and
public health before and after the 2001 anthrax attacks in the US, and the possible
impact of the attacks on international law.9 The international legal analysis sets up a
policy-oriented discussion of how bioterrorism in the United States might affect
global public health efforts. The anthrax attacks have already caused a radical change
in US domestic politics toward the long-neglected public health sector, but I raise
concerns that the attacks will divert US energies and resources away from global
public health needs.
III. TRIPS AND ACCESS TO DRUGS AND MEDICINES IN
DEVELOPING COUNTRIES
The next three contributions take up perhaps the most controversial
international legal issue in the context of infectious diseases-the impact of the
WTO's Agreement on Trade-Related Aspects of Intellectual Property Rights
("TRIPS") on developing countries' access to drugs and medicines. Ellen 't Hoen
reviews the problem TRIPS poses for developing countries' access to new drugs and
medicines." She discusses the TRIPS debate by looking at key developments,
including the role played by NGOs pushing for greater access for developing
countries. The article then analyzes the "breakthrough" event of the WTO
Declaration on TRIPS and Public Health adopted at the November 2001 WTO
ministerial meeting in Doha, Qatar ("Doha Declaration"'). Arguing that the Doha
Declaration represents a victory for developing-country access, 't Hoen looks ahead to
the post-Doha agenda, which includes implementing the Doha victory and advocating
for more research and development for drugs and vaccines to fight infectious diseases
8. See, for example, George Alberti, Noncommunicable Diseases: Tomorrow's Pandemics, 79 Bull of World
Health Org 907 (2001) (urging that non-communicable diseases are "the new pandemics of the 21"
century [that] threaten to swamp the meager health care resources of many countries.").
9. See David P. Fidler, Bioterrorism, Public Health, and International Law, 3 ChiJ Intl L 7 (2002).
10. See Ellen 't Hoen, TRIPS, Pharmaceutical Patents, and Access to Essential Medicines: A Long Way from
Seattle to Doha, 3 ChiJ Intl L 27 (2002).
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predominantly suffered in developing countries. She suggests an international treaty
fostering research and development on these neglected diseases as a way to advance
this agenda.
Alan Sykes also takes up the patents/access dispute analyzed by 't Hoen, but he
seeks to show that the Doha Declaration may adversely affect public health in
developing countries." Using legal and economic analysis, Sykes argues that the Doha
solution of encouraging developing states to engage in compulsory licensing and
parallel importation of pharmaceuticals may actually harm those same developing
countries by reducing not only pharmaceutical innovation but also access to affordable
drugs. In addition, Sykes argues that the Doha Declaration will hurt pharmaceutical
innovation on neglected diseases in the South because firms in developing countries
face the same disincentives that Doha creates for pharmaceutical companies in the
North. Sykes acknowledges that more empirical research on the access/patents issue
is needed, but suggests that the Doha Declaration may move the global community in
the wrong public health direction.
Carlos Correa deepens the controversy over the relationship between TRIPS
and access to pharmaceuticals in developing countries by analyzing the scope of the
protection afforded to test data (for example, efficacy, effectiveness, and safety
information from animal studies and clinical trials) submitted to drug regulatory
agencies in connection with product approval and registration. 2 Pharmaceutical
companies, supported by the United States, want test data protected from subsequent
use by government authorities and companies relating to the subsequent registration
of similar products, such as generics. Developing countries believe that this
"exclusivity model" would force local generic drug companies to complete costly and
redundant trials and studies. Undertaking a close analysis of TRIPS through the
Vienna Convention on the Law of Treaties, Correa concludes that TRIPS does not
enshrine the exclusivity model. He argues, rather, that it allows developing countries
discretion in how they treat test data on pharmaceutical products, creating more
opportunities for competition from generic products and thus, potentially, more
affordable access in developing countries.
IV. GLOBAL HEALTH GOVERNANCE IN A MULTI-CULTURAL
WORLD
Obijiofor Aginam focuses on multilateral governance initiatives on malaria, and
how these initiatives neglect to seek input from communities that suffer from
11. See Alan 0. Sykes, TRIPS, Pharmaceuticals, Developing Countries, and the Doba "Solution," 3 ChiJ Intl L
47 (2002).
12. See Carlos Maria Correa, Unfair Competition Under the TRIPS Agreement: Protection of Data Submitted
for the Registration of Pharmaceuticals, 3 ChiJ Intl L 69 (2002).
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malaria. 3 He reviews WHO's Roll Back Malaria ("RBM") program and the
Medicines for Malaria Venture ("MMV"), which both represent new efforts to
address malaria's impact around the world, especially in sub-Saharan Africa. While
praising these initiatives, Aginam argues that they nonetheless represent
"globalization-from-above" because they ignore indigenous approaches to treating
malaria in Africa. He cites the tension between Western medicine and traditional
medicine as one reason underlying the failure of RBM and MMV to include input
from the "peripheries" or "the voices of rural populations" in Africa. He urges that
RBM and MMV should involve more "globalization-from-below" in order to ensure
that global governance on malaria is multi-cultural. He concludes this task would
require: (1) the "scientification" of traditional medical therapies for malaria; (2) global
governance mechanisms that respect globalization-from-below; and (3) the protection
of traditional medical knowledge from "biopiracy" within international intellectual
property law.
V. HUMAN RIGHTS AND PUBLIC HEALTH
The final two contributions highlight the importance of international human
rights law to national and global public health issues. Mary Ann Torres analyzes
access to HIV/AIDS therapies in Venezuela within the framework of the human
right to health.'4 Her focus is on a Venezuelan Supreme Court case in which the
Court held that HIV+ Venezuelans had the right to receive antiretroviral therapy
from the government under the human right to health enshrined in the Venezuelan
constitution, as well as under treaties Venezuela has ratified. Torres illustrates the
importance of national implementation of human rights and the need for local action
to make the right to health more real. The case also raises difficult questions about
the role of national courts in connection with the right to health and governmental
efforts to prevent and control HIV/AIDS. The Venezuelan Supreme Court ordered
the Ministry of Health to supply HIV+ persons with antiretroviral therapy, even
when the legislature had not allocated sufficient funds to enable the Ministry to
undertake such an effort. This case further highlights the difficulty of progressively
realizing the right to health in developing countries that have limited public health
budgets.
Stephen Marks's paper analyzes international law as it relates to human genetic
manipulation and concentrates on the human rights issues that such manipulation
13. See Obijiofor Aginam, From the Core to the Peripheries: Multilateral Governance of Malaria in a Multi-
Cultural World, 3 ChiJ Intl L 87 (2002).
14. See Mary Ann Torres, The Human Right to Health, National Courts, and Access to HIV/AIDS
Treatment. A Case Study from Venezuela, 3 ChiJ Intl L 105 (2002).
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raises." Genetic engineering has created hopes about the health benefits biotechnology
may produce, such as finding ways to eliminate life-threatening diseases. It has also
generated fears about the dangers of tinkering with the human genome. Marks
outlines two perspectives that animate debates about human genetic manipulation-
the essentialist, welfare-state position and the utilitarian, neoliberal position. These
perspectives support two bodies of international law that are in tension-human
rights law and the law that protects intellectual property rights. Marks then discusses
human genetic manipulation in connection with three categories of human rights
present in international law: (1) rights that relate to the nature and autonomy of the
human person; (2) rights that relate to physical and mental integrity and well-being;
and (3) rights dealing with social relations and participation. He concludes by looking
at non-governmental and intergovernmental proposals for treaties that would regulate
human genetic manipulation, including a European effort at the United Nations
advocating a convention banning human cloning. Where human genetic
manipulation takes human health, Marks argues, remains uncertain, as does the
extent to which international law will be used to encourage or restrain the biotech
Prometheus.
VI. CONCLUSION
From the moment public health became a matter of international diplomacy in
the mid-nineteenth century, international law has been a tool both used and ignored
in the global efforts against disease. The contributions in this symposium suggest that
the future of national and global governance of public health in the twenty-first
century involves a significant role for international law. How the role of international
law in this realm is shaped deserves heightened attention from the international legal
community.
15. See Stephen P. Marks, Tying Prometheus Down: The International Law of Human Genetic Manipulation,
3 ChiJ Intl L 115 (2002).
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